U.S. Logistics Stock News

Abbott Laboratories (ABT) just expanded its cancer diagnostics reach through a new integration with Flatiron Health’s OncoEMR, giving more than 1,600 community cancer centers streamlined access to its Precision Oncology testing portfolio. See our latest analysis for Abbott Laboratories. Despite the oncology integration and other recent moves such as the ESOP related shelf registration and investment in Whoop, Abbott’s 30 day share price return of 10.29% and year to date share price return of...

Planet Labs PBC (PL) is back in focus after filing a US$680.7m shelf registration tied to an ESOP related offering, alongside fresh quarterly results, wider net losses, and new revenue guidance. See our latest analysis for Planet Labs PBC. After the shelf filing and earnings release, Planet Labs PBC’s 1-day share price return of 9.87% contrasts with a 7-day share price return of negative 13.18%. A 90-day share price return of 55.73% sits alongside a 1-year total shareholder return of about...

KULR Technology Group (KULR) closed FY 2025 with fourth quarter revenue of US$2.9 million and a basic EPS loss of US$0.97, alongside a trailing twelve month EPS loss of US$1.56 on revenue of US$16.2 million. Over the last few quarters, the company has reported revenue between US$2.4 million and US$6.9 million per quarter, while quarterly EPS has ranged from a loss of US$0.54 to a gain of US$0.22. This leaves investors focusing on how quickly these top line changes might translate into...

FitLife Brands (FTLF) has just closed out FY 2025 with fourth quarter revenue of US$25.9 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$81.5 million and EPS of US$0.68 that investors will be watching against the prior year’s figures. Over recent quarters the company has seen revenue move from US$15.0 million in Q4 FY 2024 to US$25.9 million in Q4 FY 2025, while quarterly EPS shifted from US$0.23 to US$0.17, setting the backdrop for the latest full year read on...

Check Point Software Technologies (CHKP) closed out FY 2025 with fourth quarter revenue of US$744.9 million and basic EPS of US$2.85, while full year trailing EPS reached US$9.85 on revenue of US$2.7 billion and earnings grew 25% over the past 12 months. Over the last few reported periods, revenue has moved from US$703.7 million in Q4 2024 to US$744.9 million in Q4 2025, with quarterly basic EPS ranging from US$1.77 in Q1 2025 to US$3.34 in Q3 2025 and trailing net income rising from US$845.7...

Dawson Geophysical (DWSN) closed out FY 2025 with fourth quarter revenue of US$26.9 million and basic EPS of US$0.02, alongside net income of US$0.6 million. This set a cleaner finish to a year where the trailing twelve month figures still show a loss of US$1.9 million on US$75.6 million of revenue and a basic EPS loss of US$0.06. Over recent quarters the company has seen quarterly revenue range from US$9.9 million to US$26.9 million, with EPS moving between a loss of US$0.08 and a profit of...

IDEAYA Biosciences (IDYA) recently reported the first patient enrolled in a Phase 1 trial combining IDE849, a DLL3 targeting antibody drug conjugate, with PARG inhibitor IDE161 in several DLL3 upregulated solid tumors. See our latest analysis for IDEAYA Biosciences. The Phase 1 combination update has come as IDEAYA’s share price has eased slightly in the short term, with a 7 day share price return of 3.47% and a 1 year total shareholder return close to 100%. This reflects how recent trial...

ABM Industries stock: recent returns and business mix in focus ABM Industries (ABM) has drawn investor attention after a one-month return of about a 13% decline, adding to a past three-month drop of roughly 9%. This performance has invited closer inspection of its fundamentals. See our latest analysis for ABM Industries. With the share price at $38.70, ABM Industries has seen weaker momentum recently, with a 30 day share price return of a 13.44% decline and a 1 year total shareholder return...

If you are wondering whether Kosmos Energy's share price still reflects its underlying worth, the recent moves in the stock make that question especially timely. The stock last closed at US$2.78, with returns of 2.2% over 7 days, 19.3% over 30 days, 211.4% year to date and 23.6% over 1 year, set against a 64.3% decline over 3 years and a 9.2% decline over 5 years. Recent news coverage has focused on Kosmos Energy's positioning within the energy sector and how investors are reacting to...

In late March 2026, Rockwell Automation released a new season of its ROKStudios executive video series, spotlighting manufacturing leaders across EMEA discussing cyber resilience, workforce transformation, packaging innovation, and the shift from traditional automation to more autonomous industrial operations. This content push underscores how Rockwell is positioning itself at the center of industry debates on digital complexity, resilience, and AI-enabled industrial workflows, aligning its...

In late March 2026, UWM Holdings CEO Mat Ishbia and SFS Holding Corp sold 3,001,722 Class A shares, shortly after the company reported fourth-quarter 2025 revenue of US$945.00 million that exceeded forecasts and announced advisory and proxy work around its proposed acquisition of Two Harbors Investment Corp. This combination of insider selling, stronger-than-expected quarterly results, and an active acquisition process highlights a period of meaningful corporate change and heightened...

Silicon Motion Technology (NasdaqGS:SIMO) is expanding its automotive grade NAND storage controller portfolio for connected and AI focused vehicles. The company is aligning products with automotive safety and cybersecurity standards such as AEC-Q100, ISO 26262, ISO 21434, and ASPICE Level 3. Its embedded storage solutions are being tailored for advanced driver-assistance systems and autonomous driving platforms. For readers following NasdaqGS:SIMO, this push into automotive storage sits on...

Futu Holdings Limited recently received an upgrade to a Zacks Rank #1 (Strong Buy), reflecting a shift toward more positive analyst earnings estimates and sentiment around its profit outlook. This change highlights how analyst estimate revisions can influence perceptions of Futu’s earnings power and the sustainability of its international, technology-led brokerage model. We’ll now examine how this Zacks Rank upgrade and brighter earnings outlook interact with Futu’s existing investment...

If you are wondering whether AbbVie at around US$214.98 is a fair deal or a stretch at current levels, this article walks through what the numbers are actually saying about the stock's value. The share price performance has been mixed, with a 3.8% gain over the last 7 days, an 8.2% decline over the last 30 days, a 6.2% decline year to date, an 8.3% return over 1 year, and very large gains of 49.0% and 147.4% across 3 and 5 years. Recent attention on AbbVie has focused on its position as a...

What BrightSpring’s recent performance data means for investors BrightSpring Health Services (BTSG) has attracted attention after recent trading data showed a 1.4% decline over the past day and a 6.2% pullback over the past week, alongside positive longer term returns. See our latest analysis for BrightSpring Health Services. Despite the recent 1-day and 7-day share price declines, BrightSpring’s 90-day share price return of 12.23% and very large 1-year total shareholder return of 131.19%...

The U.S. Justice Department has unsealed an indictment against three individuals linked to Super Micro Computer for allegedly diverting advanced Nvidia-powered servers worth about US$2.50 billions to Chinese customers in breach of U.S. export controls, triggering multiple shareholder class actions accusing the company of misleading disclosures on sales and compliance. Although Super Micro itself has not been named as a defendant, the involvement of a co-founder, governance upheaval, and...

Dianthus Therapeutics recently reported an early “GO” decision in its late-stage CAPTIVATE trial of claseprubart for chronic inflammatory demyelinating polyneuropathy, after meeting interim responder goals ahead of schedule. The US FDA also agreed to multiple company-proposed changes across claseprubart’s development program, including updated screening criteria, lab work, and autoimmune safety monitoring, potentially streamlining current and future studies. We’ll now examine how the early...

Hesai Group recently reported its fourth-quarter and full-year 2025 results, turning a prior-year loss into net income of CNY 435.88 million on CNY 3,027.57 million in sales, and entered a 2026 Supply of Products Framework Agreement under which it will provide LiDAR products and robotic actuators plus manufacturing and support services to Sharpa. By pairing improved profitability with a new Physical AI-focused partnership that bundles hardware and integration services, Hesai is broadening...

Arcutis Biotherapeutics (ARQT) is back in focus after new INTEGUMENT-INFANT Phase 2 data on ZORYVE cream 0.05% in infants with mild to moderate atopic dermatitis, supporting a planned supplemental New Drug Application. See our latest analysis for Arcutis Biotherapeutics. The new clinical data arrives after a mixed stretch for the shares, with a 1-day share price return of 10.45% and 7-day share price return of 7.92% contrasting with a 30-day share price return decline of 12.64%. However, a...

IDEXX Laboratories (IDXX) has drawn fresh attention after introducing its IDEXX Cancer Dx Panel in the United Kingdom, offering blood test based early detection of lymphoma in at risk dogs and expanding its veterinary diagnostics reach. See our latest analysis for IDEXX Laboratories. Despite the product launch and earlier trading spikes, momentum in the share price has cooled, with a 30 day share price return of a 14.44% decline and a year to date share price return of a 16.13% decline, while...

If you are wondering whether Aflac at around US$109.64 is offering fair value or a potential bargain, this article walks through what the current price might be indicating. The stock has been relatively steady recently, with a 2.3% return over the last 7 days, a 3.3% decline over 30 days, and returns of 0.5% decline year to date and 0.2% decline over 1 year, set against much stronger 3 year and 5 year returns of 81.6% and 137.7%. Recent coverage around Aflac has focused on its role as a...

Wondering if Home Depot at around US$329.56 is priced for opportunity or caution? This article breaks down what the current share price might be telling you about value. The stock is down about 0.9% over the last week and 11.1% over the past month, with returns of a 4.7% decline year to date and an 8.9% decline over the last year, but still shows a 23.1% gain over three years and 19.2% over five years. These moves are unfolding against a backdrop where investors are paying close attention to...

Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2. The late stage Brilliance Studies aim to evaluate alixorexton in patients with significant unmet treatment needs in sleep disorders. This marks a new development in Alkermes' pipeline beyond prior focus areas highlighted in earlier coverage. For Alkermes, known for its work in neuroscience and psychiatry, the Brilliance Studies add a new dimension to...

EQT (NYSE:EQT) is advancing its post Olympus Energy integration by preparing multi bench drilling across the Marcellus and Utica formations. The company is conducting field surveys in Upper Burrell, Pennsylvania, as it plans new lateral wells in previously untapped areas. This shift marks a move away from a single target drilling approach toward broader development of its Appalachian acreage. EQT, trading at $61.09, is entering this next phase after a period where attention largely centered...